BioAge Labs Doses First Participant in Phase 2 QUELL-CV Trial for BGE-102
BioAge Labs announced the dosing of the first participant in QUELL-CV, a Phase 2 clinical trial for BGE-102, its lead product candidate for cardiovascular risk reduction. The trial is a randomized, double-blind, placebo-controlled, dose-ranging study evaluating three once-daily oral doses in approximately 160 adults with elevated systemic inflammation and cardiovascular risk factors. The primary endpoint is the percent change in high-sensitivity C-reactive protein (hsCRP), with topline data expected in the second half of 2026. This builds on positive Phase 1 results where BGE-102 achieved significant hsCRP reductions and was well tolerated. BioAge also plans to initiate a Phase 1b/2a trial for BGE-102 in diabetic macular edema in mid-2026.
Key Highlights
- First participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial for BGE-102.
- QUELL-CV is a randomized, double-blind, placebo-controlled, dose-ranging trial.
- Trial evaluates three once-daily oral doses of BGE-102 (30 mg, 60 mg, 90 mg).
- Approximately 160 adults with obesity, elevated hsCRP (>3 mg/L) are enrolled.
- Primary endpoint is percent change from baseline in high-sensitivity C-reactive protein (hsCRP).
- Topline data from QUELL-CV are anticipated in the second half of 2026.
- Phase 1 results showed median hsCRP reductions of 86% at 60 mg and 120 mg doses.
- Company plans to initiate a Phase 1b/2a trial for BGE-102 in diabetic macular edema mid-2026.
Price Impact
More from BIOA